Moderna cautious consensus builds, shares reflect mixed analyst views
28.06.2026 - 11:56:34 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 11:56.
Moderna Inc. (US60770K1034) sits in focus as analysts reassess its outlook beyond COVID vaccines. The NASDAQ-listed S&P 500 constituent draws a spread of ratings and fresh price targets on the back of its mRNA pipeline developments, according to recent analyst notes and market commentary.
What Piper Sandler highlights
Piper Sandler recently maintained its Overweight stance on Moderna and raised the price target to 77 US dollars from 69 US dollars, citing expanding applications of its mRNA platform in oncology and autoimmune indications. This update, referenced in a market summary that attributes the move to pipeline progress, underscores that at least one major US research house remains constructive on the stock despite past volatility. Intellectia.ai summary citing Piper Sandler and Seeking Alpha
Recent trading data compiled by MarketBeat shows Moderna shares last closing around the mid-60s US dollars range, after double-digit percentage moves in late June tied to updates on in vivo CAR-T research and flu vaccine advances, according to aggregated headlines. These moves emphasise that catalysts from clinical research and portfolio expansion can quickly reshape sentiment and pricing for the NASDAQ-listed biotech. MarketBeat overview of recent Moderna news and prices
How consensus on Moderna looks
Across the broader analyst community, consensus data compiled by several financial platforms points to a mix of Buy, Hold and occasionally Underperform ratings on Moderna, with not all houses sharing Piper Sandler's constructive stance. In aggregated coverage, price targets cluster in a band from roughly the high-50s to the mid-70s US dollars, highlighting cautious optimism but limited agreement on the pace at which new indications will translate into revenue.
Commentary pieces that compare Moderna with established vaccine peers such as Merck and Pfizer underline that the company remains more volatile and pipeline-dependent than Big Pharma incumbents. One recent analysis framed Moderna's strong daily gain as part of a broader move among vaccine and biotech names, but noted that its long-term performance and valuation still hinge on successfully commercialising non-COVID assets in infectious disease and oncology. Finanzen100 summary of Moderna news and sector comparison
Background and price data on Moderna
All recent news, price movements and regulatory filings for the Moderna shares are collected on the ad-hoc-news topic page and on the company's Investor Relations site.
What the company sells
Moderna's core business is built around its mRNA technology platform, with its best-known product being the Spikevax COVID-19 vaccine, which has been deployed globally since emergency authorisations in 2020 and 2021. Beyond COVID, Moderna is advancing late-stage candidates in respiratory syncytial virus (RSV) vaccination and personalised cancer vaccines, aiming to turn its research pipeline into diversified, recurring revenue streams. The company also explores autoimmune and rare disease applications using the same mRNA approach, positioning itself as a platform biotech rather than a single-product firm.
Where the stock trades today
Moderna shares (US60770K1034) trade on NASDAQ, with recent closing data around the mid-60s US dollars region as per late-June market snapshots, reflecting both the impact of pipeline news and changing analyst expectations on the biotech's medium-term growth profile.
Key data on the Moderna shares
- Company: Moderna Inc.
- ISIN: US60770K1034
- WKN: A2N9D9
- Ticker: MRNA
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 16:00): 67.27 USD
- Market cap: around 27 billion USD (as of late June 2026)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any financial instrument. All data are based on sources deemed reliable but cannot be guaranteed.
